| CD34+ Transplants for Leukemia and Lymphoma (NCT05565105) | Guenther Koehne | 2026-06-01 |
| The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching (NCT07678645) | RenJi Hospital | 2026-06-01 |
| GD2/CD56 Bi-specific CAR-T Cell Therapy (NCT05437328) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC (NCT07603661) | Sun Yat-sen University | 2026-06-01 |
| Study of QLS1410 in the Treatment of Primary Aldosteronism. (NCT07550465) | Qilu Pharmaceutical Co., Ltd. | 2026-06-01 |
| Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD (NCT06386003) | Unity Health Toronto | 2026-06-01 |
| Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) (NCT07584031) | Tianjin Medical University Cancer Institute and Hospital | 2026-06-01 |
| Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors (NCT07671534) | Sarcoma Oncology Research Center, LLC | 2026-06-01 |
| All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis (NCT07626398) | Beijing Anzhen Hospital | 2026-06-01 |
| Ivarmacitinib for Refractory Behcet's Syndrome (NCT07634848) | Liu Tian | 2026-06-01 |
| A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia (NCT06712654) | R1 Therapeutics | 2026-06-01 |
| HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer (NCT07587034) | Shanghai Zhongshan Hospital | 2026-06-01 |
| Folate Study in Men With Advanced Prostate Cancer (NCT06536374) | University of California, San Diego | 2026-06-01 |
| CD19/70 Bi-specific CAR-T Cell Therapy (NCT05436496) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| siRNA Microneedle Patches for Ear Keloid Post-Surgical Scars (NCT07596628) | Ong Kim Yao | 2026-06-01 |
| Impact of Formulation Change on Ovarian Suppression in Young Breast Cancer Patients. (NCT07610733) | Fudan University | 2026-06-01 |
| Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients With Spinocerebellar Palsy (NCT07467733) | Biocells Medical | 2026-06-01 |
| VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. (NCT07642453) | Hematology department of the 920th hospital | 2026-06-01 |
| Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation (NCT07249346) | Hannah Choe, MD | 2026-06-01 |
| Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC (NCT04298541) | Weill Medical College of Cornell University | 2026-06-01 |
| Effect of Ipratropium Bromide on EILO (NCT07394036) | Cook Children's Health Care System | 2026-06-01 |
| To Evaluate the Efficacy and Safety of QL2401 in Patients With Metabolic Dysfunction-associated Steatohepatitis and Liver Fibrosis (F2-F3) (NCT07620366) | Qilu Pharmaceutical Co., Ltd. | 2026-06-01 |
| Ketone Monitoring Approaches for Diabetic Ketoacidosis Risk Mitigation in People With T1D on Adjunctive SGLT-2 Inhibitors (NCT07421518) | AdventHealth Translational Research Institute | 2026-06-01 |
| Repeated Administration of Cannabis Varying in THC and CBD (NCT05563948) | New York State Psychiatric Institute | 2026-06-01 |
| A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies (NCT07503353) | Sheba Medical Center | 2026-06-01 |
| Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL (NCT07643805) | The First Affiliated Hospital with Nanjing Medical University | 2026-06-01 |
| A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis (NCT07598383) | Jiangsu vcare pharmaceutical technology co., LTD | 2026-06-01 |
| A Study of IDP-001 in Advanced or Metastatic Solid Tumors (NCT07602842) | InduPro, Inc. | 2026-06-01 |
| Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma (NCT07622784) | Sun Yat-sen University | 2026-06-01 |
| Atropine Eye Drops for Watery Eyes (Excessive Tearing) (NCT07676981) | Rehan Ahmed | 2026-06-01 |
| Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (NCT07494435) | Zhejiang Haichang Biotech Co., Ltd. | 2026-06-01 |
| A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis (NCT07622342) | Guangdong Hengrui Pharmaceutical Co., Ltd | 2026-06-01 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies (NCT04033302) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Treatment of Recurrent/Metastatic Head and Neck Cancer (NCT07601204) | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 2026-06-01 |
| Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer (NCT07618923) | Tang-Du Hospital | 2026-06-01 |
| Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women (NCT06197568) | Azure Biotech Inc. | 2026-06-01 |
| Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs (NCT07152379) | Cerus Corporation | 2026-06-01 |
| Iparomlimab Tolvorlimab as Neoadjuvant Immunotherapy for Locally Advanced Gastric Adenocarcinoma With Microsatellite Instability/Mismatch Repair Deficiency (NCT07595523) | Peking University Cancer Hospital & Institute | 2026-06-01 |
| CD19/79b Bi-specific CAR-T Cell Therapy (NCT05436509) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| A Safety Study of Contralateral Eye Dosing of VGR-R01 in Participants With Bietti's Crystalline Dystrophy (BCD) (NCT07586306) | Shanghai Vitalgen BioPharma Co., Ltd. | 2026-06-01 |
| Fecal Microbiota Transplantation for Elderly Patients With HFpEF: A Randomized Controlled Trial (NCT07628777) | The First Affiliated Hospital of Air Force Medicial University | 2026-06-01 |
| Engineered Immune Effectors Against Ovarian Cancer (NCT03362606) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC (NCT05423197) | Andrei Iagaru | 2026-06-01 |
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer (NCT04427449) | Shenzhen Geno-Immune Medical Institute | 2026-06-01 |
| Intraperitoneal Irrigation of Ondansteron in Combination With Lidocaine in Acute Postoperative Pain (NCT07706348) | Assiut University | 2026-06-01 |
| Valbenazine in Obsessive Compulsive Disorder (NCT07111988) | University of Chicago | 2026-06-01 |
| SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss (NCT01451853) | Sound Pharmaceuticals, Incorporated | 2026-06-01 |
| SCI-110 in the Treatment of Tourette Syndrome (NCT05126888) | Neurothera Labs Inc. | 2026-06-01 |
| Cannabidiol Oil for Treatment-Resistant Major Depression (NCT07696871) | Universidade do Sul de Santa Catarina | 2026-06-01 |
| A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) (NCT07601074) | Daré Bioscience, Inc. | 2026-06-01 |
| Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma (NCT07602101) | RenJi Hospital | 2026-05-31 |
| Study to Investigate the Efficacy and Safety of Apomivir® (NCT01677689) | Far East Bio-Tec Co., Ltd | 2026-05-31 |
| Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy (NCT07627464) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-31 |
| Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR (NCT07651007) | Wang Xin | 2026-05-31 |
| TGD001 Treatment in Thrombotic Microangiopathies (NCT07459114) | TargED Biopharmaceuticals B.V. | 2026-05-31 |
| Doxycycline Use in Post-Operative Seromas (NCT07498010) | University of Miami | 2026-05-31 |
| A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） (NCT07519577) | Keymed Biosciences Co.Ltd | 2026-05-31 |
| Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma (NCT07584733) | RenJi Hospital | 2026-05-31 |
| Evaluation of the Efficacy and Safety of LW402 Tablets in Patients With Non-Segmental Vitiligo (NCT07556471) | Shanghai Longwood Biopharmaceuticals Co., Ltd. | 2026-05-31 |
| Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours (NCT07594028) | Sinocelltech Ltd. | 2026-05-30 |
| The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease (NCT07457125) | Xuanwu Hospital, Beijing | 2026-05-30 |
| A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer (NCT07545044) | Shanghai JMT-Bio Inc. | 2026-05-30 |
| Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC? (NCT07625527) | Tianjin Medical University Second Hospital | 2026-05-30 |
| Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (NCT07601607) | Sun Yat-sen University | 2026-05-30 |
| Zorifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progression in NSCLC After Third-Generation EGFR-TKI (NCT07551414) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2026-05-30 |
| Sublingual Oxytocin for the Prevention of Post-partum Hemorrhage (NCT06968481) | Insud Pharma | 2026-05-30 |
| Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma (NCT07622706) | Peking University Cancer Hospital & Institute | 2026-05-30 |
| Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC (NCT07618910) | Tang-Du Hospital | 2026-05-30 |
| Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases (NCT07570914) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-30 |
| Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease (NCT07280299) | Gain Therapeutics, Inc. | 2026-05-30 |
| Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer (NCT07591831) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-30 |
| A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer (NCT07446387) | Jiangsu Cancer Institute & Hospital | 2026-05-30 |
| A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk (NCT07515469) | Tianjin Medical University Cancer Institute and Hospital | 2026-05-30 |
| Gemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies (NCT07599995) | Sir Run Run Shaw Hospital | 2026-05-30 |
| SLN12140 in Adult Participants With IgA Nephropathy in China (NCT07553494) | Linno Pharmaceuticals, Inc. | 2026-05-29 |
| Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation (NCT07687433) | Harbin Medical University | 2026-05-29 |
| SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid Tumors (NCT07622225) | CSPC Megalith Biopharmaceutical Co.,Ltd. | 2026-05-29 |
| Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (NCT06965114) | National Cancer Institute (NCI) | 2026-05-29 |
| Single-arm, Phase II Clinical Study Evaluating the Safety and Efficacy of Sintilimab Combined With IBI-310 and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer (NCT07750951) | Xijing Hospital | 2026-05-29 |
| Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab (NCT07387198) | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2026-05-29 |
| A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence (NCT07598708) | Centessa Pharmaceuticals (UK) Limited | 2026-05-29 |
| A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia (NCT07610278) | Novartis Pharmaceuticals | 2026-05-29 |
| Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma (NCT07615283) | Sun Yat-sen University | 2026-05-29 |
| Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss (NCT07627971) | Skylark Bio Inc. | 2026-05-28 |
| Improving Preterm Kidney Outcomes With Caffeine (NCT07262060) | University of Wisconsin, Madison | 2026-05-28 |
| Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma (NCT07744529) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2026-05-28 |
| A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae (NCT07647029) | Fudan University | 2026-05-28 |
| A Study of Lower Dose Radiation Therapy for People With Prostate Cancer (NCT07635238) | Memorial Sloan Kettering Cancer Center | 2026-05-28 |
| A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade (NCT07459166) | Clear Scientific, Inc. | 2026-05-28 |
| A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis (NCT07470879) | Pfizer | 2026-05-28 |
| Dapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus Nephritis (NCT07678203) | Hospital Civil Juan I. Menchaca | 2026-05-28 |
| Deucravacitinib in the Treatment of Cicatricial Alopecias (NCT07508488) | Icahn School of Medicine at Mount Sinai | 2026-05-28 |
| A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity. (NCT07570758) | ERX Pharmaceuticals | 2026-05-28 |
| tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy (NCT07433023) | Shirley Ryan AbilityLab | 2026-05-28 |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis (NCT07599813) | Apollo Therapeutics Ltd | 2026-05-28 |
| Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy (NCT07434492) | Shirley Ryan AbilityLab | 2026-05-28 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (NCT06980038) | National Cancer Institute (NCI) | 2026-05-27 |
| Safety and Efficacy of PTH-IA (NCT07541209) | National Institute of Dental and Craniofacial Research (NIDCR) | 2026-05-27 |
| A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer (NCT07631000) | Memorial Sloan Kettering Cancer Center | 2026-05-27 |
| Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors (NCT07512583) | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 2026-05-27 |